.jpg "Inovio Pharmaceuticals (NASDAQ: INO)")
Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals (INO) today and set a price target of $8. The company’s shares opened today at $4.55.
McCarthy commented:
“Inovio announced the publication of a preclinical study highlighting the successful development of optimized DNA-encoded monoclonal antibodies (dMABs) targeting the immune checkpoint PD-1.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.0% and a 27.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, implying a 130.8% upside from current levels. In a report issued on January 8, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.30 and a one-year low of $3.64. Currently, Inovio Pharmaceuticals has an average volume of 883.7K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2018, Avtar Dhillon, a Director at INO bought 25,000 shares for a total of $50,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
